Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus

Nature Genetics

Volumn 49, Issue 5, 2017, Pages 666-673

  Ansari, M Azim ^a,b,c   Pedergnana, Vincent ^a   Ip, Camilla L C ^a,c   Magri, Andrea ^c   Von Delft, Annette ^c   Bonsall, David ^c   Chaturvedi, Nimisha ^d   Bartha, Istvan ^d   Smith, David ^c   Nicholson, George ^e   McVean, Gilean ^a,c   Trebes, Amy ^a   Piazza, Paolo ^a   Fellay, Jacques ^d   Cooke, Graham ^f   Foster, Graham R ^g   Hudson, Emma ^c   McLauchlan, John ^h   Simmonds, Peter ^c   Bowden, Rory ^a   Klenerman, Paul ^c   Barnes, Eleanor ^c   Spencer, Chris C A ^a   Ball, Jonathan ^k   Brainard, Diana ^l   Burgess, Gary ^m   Dillon, John ⁿ   Gore, Charles ^o   Guha, Neil ^k   Halford, Rachel ^o   Herath, Cham ^p   Holmes, Chris ^e   Howe, Anita ^q   Irving, William ^k   Khakoo, Salim ^r   Koletzki, Diana ^s   Martin, Natasha ^t   Massetto, Benedetta ^l   Mbisa, Tamyo ^u   McHutchison, John ^l   McKeating, Jane ^c   Miners, Alec ^v   Murray, Andrea ^w   Shaw, Peter ^x   Targett Adams, Paul ⁱ   Thomson, Emma ^h   Vickerman, Peter ^j   Zitzmann, Nicole ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d EPFL   (Switzerland)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

ⁱ MEDIVIR AB   (Sweden)

^j UNIVERSITY OF BRISTOL   (United Kingdom)

^k UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^l GILEAD SCIENCES   (United States)

^m Gilead Sciences ^*  (United States)

ⁿ UNIVERSITY OF DUNDEE   (United Kingdom)

^o Hepatitis C Trust   (United Kingdom)

^p Stockley Park   (United Kingdom)

^q ST PAUL S HOSPITAL   (Canada)

^r UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^s JANSSEN RESEARCH FOUNDATION   (Belgium)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u PUBLIC HEALTH ENGLAND   (United Kingdom)

^v LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^w NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^x MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HLA ANTIGEN; NONSTRUCTURAL PROTEIN 5A; IFNL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADAPTIVE IMMUNITY; ALLELE; ARTICLE; CONTROLLED STUDY; GENE STRUCTURE; GENOME ANALYSIS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VIRUS GENE; VIRUS GENOME; VIRUS LOAD; CHRONIC HEPATITIS C; GENETIC VARIATION; GENETICS; HEPACIVIRUS; HOST PATHOGEN INTERACTION; HUMAN GENOME; PHYSIOLOGY; PRINCIPAL COMPONENT ANALYSIS; STATISTICAL MODEL; VIROLOGY;

ADAPTIVE IMMUNITY; ALLELES; GENETIC VARIATION; GENOME, HUMAN; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HLA ANTIGENS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTERLEUKINS; LOGISTIC MODELS; PRINCIPAL COMPONENT ANALYSIS; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85017255964     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3835     Document Type: Article

References (64)

1. Mohd Hanafiah, K., Groeger, J., Flaxman, A.D. & Wiersma, S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333-1342 (2013).
2. Thomas, D.L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801 (2009).
3. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
4. Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338-1345 (2010).
5. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
6. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
7. Enomoto, N. et al. Mutations in the nonstructural protein 5a gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334, 77-82 (1996).
8. Pascu, M. et al. Sustained virological response in hepatitis C virus type 1b-infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53, 1345-1351 (2004).
9. Halfon, P. & Locarnini, S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 55, 192-206 (2011).
10. Halfon, P. & Sarrazin, C. Future treatment of chronic hepatitis C with direct-acting antivirals: is resistance important? Liver Int. 32, 79-87 (2012).
11. Ahmed, A. & Felmlee, D.J. Mechanisms of hepatitis C viral resistance to direct-acting antivirals. Viruses 7, 6716-6729 (2015).
12. Sarrazin, C. et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B or NS3, and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 151, 501-512 (2016).
13. Messina, J.P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77-87 (2015).
14. Pol, S., Vallet-Pichard, A. & Corouge, M. Treatment of hepatitis C virus genotype 3 infection. Liver Int. 34 (Suppl. 1), 18-23 (2014).
15. Ampuero, J., Romero-Gómez, M. & Reddy, K.R. HCV genotype 3-the new treatment challenge. Aliment. Pharmacol. Ther. 39, 686-698 (2014).
16. Fitzmaurice, K. et al. Molecular footprints reveal the impact of the protective HLA-A∗03 allele in hepatitis C virus infection. Gut 60, 1563-1571 (2011).
17. Neumann-Haefelin, C. et al. Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. Hepatology 54, 1157-1166 (2011).
18. Heim, M.H. & Thimme, R. Innate and adaptive immune responses in HCV infections. J. Hepatol. 61 (Suppl. 1), S14-S25 (2014).
19. Swadling, L. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 6, 261ra153 (2014).
20. von Delft, A. et al. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut 65, 112-123 (2016).
21. Foster, G.R. et al. Efficacy of sofosbuvir plus ribavirin, with or without peginterferon-α, in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149, 1462-1470 (2015).
22. Bonsall, D. et al. ve-SEQ: robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. F1000 Res. 4, 1062 (2015).
23. Thomson, E. et al. Comparison of next-generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes. J. Clin. Microbiol. 54, 2470-2484 (2016).
24. Dilthey, A. et al. Multi-population classical HLA type imputation. PLoS Comput. Biol. 9, e1002877 (2013).
25. Zheng, X. et al. HIBAG-HLA genotype imputation with attribute bagging. Pharmacogenomics J. 14, 192-200 (2014).
26. Gonzalez-Galarza, F.F. et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease, and HLA adverse drug reaction associations. Nucleic Acids Res. 43, D784-D788 (2015).
27. Pe'er, I., Yelensky, R., Altshuler, D. & Daly, M.J. Estimation of the multiple-testing burden for genome-wide association studies of nearly all common variants. Genet. Epidemiol. 32, 381-385 (2008).
28. Johnson, R.C. et al. Accounting for multiple comparisons in a genome-wide association study (GWAS). BMC Genomics 11, 724 (2010).
29. de Bakker, P.I.W. et al. A high-resolution HLA and SNP haplotype map for disease-association studies in the extended human MHC. Nat. Genet. 38, 1166-1172 (2006).
30. Malkki, M., Single, R., Carrington, M., Thomson, G. & Petersdorf, E. MHC microsatellite diversity and linkage disequilibrium among common HLA-A, HLA-B, DRB1 haplotypes: implications for unrelated donor hematopoietic transplantation and disease-association studies. Tissue Antigens 66, 114-124 (2005).
31. + T cell response promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology 140, 2064-2073 (2011).
32. Merani, S. et al. Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreak. Hepatology 53, 396-405 (2011).
33. Rauch, A. et al. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology 50, 1017-1029 (2009).
34. Gaudieri, S. et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J. Virol. 80, 11094-11104 (2006).
35. Patin, E. et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 143, 1244-1252 (2012).
36. Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164-171 (2013).
37. Terczyńska-Dyla, E. et al. Reduced IFN-λ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat. Commun. 5, 5699 (2014).
38. Jacobson, I.M. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368, 1867-1877 (2013).
39. Lawitz, E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878-1887 (2013).
40. Witteveldt, J., Martin-Gans, M. & Simmonds, P. Enhancement of the replication of hepatitis C virus replicons of genotypes 1 to 4 by manipulation of CpG and UpA dinucleotide frequencies and use of cell lines expressing SECL14L2 for antiviral resistance testing. Antimicrob. Agents Chemother. 60, 2981-2992 (2016).
41. Sheahan, T. et al. Interferon-λ alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15, 190-202 (2014).
42. Bibert, S. et al. IL28B expression depends on a novel TT/-G polymorphism, which improves HCV clearance prediction. J. Exp. Med. 210, 1109-1116 (2013).
43. Ferraris, P. et al. Cellular mechanism for impaired hepatitis C virus clearance by interferon associated with IFNL3 gene polymorphisms relates to intrahepatic interferon-λ expression. Am. J. Pathol. 186, 938-951 (2016).
44. Peiffer, K.-H. et al. Interferon-λ4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology 63, 63-73 (2016).
45. Pedergnana, V. et al. Interferon-λ4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a. Hepatology 64, 1377-1378 (2016).
46. McHutchison, J.G. et al. Peginterferon-α2b or α2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361, 580-593 (2009).
47. Bochud, P.-Y. et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55, 384-394 (2012).
48. Thompson, A.J. et al. Interleukin 28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139, 120-129 (2010).
49. Tellinghuisen, T.L., Foss, K.L. & Treadaway, J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 4, e1000032 (2008).
50. Jia, X. et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 8, e64683 (2013).
51. Chang, C.C. et al. Second-generation PLINK: rising to the challenge of larger and richer data sets. Gigascience 4, 7 (2015).
52. Lamble, S. et al. Improved workflows for high-throughput library preparation using the transposome-based Nextera system. BMC Biotechnol. 13, 104 (2013).
53. Gaidatzis, D., Lerch, A., Hahne, F., Stadler, M.B. & Quas, R. Quantification and annotation of short reads in R. Bioinformatics 31, 1130-1132 (2015).
54. Martin, M. Cutadapt removes adapter sequences from high-throughput-sequencing reads. EMBnet.journal 17, 10 (2011).
55. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
56. Smith, D.B. et al. Expanded classification of hepatitis C virus into seven genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59, 318-327 (2014).
57. Yang, X. et al. De novo assembly of highly diverse viral populations. BMC Genomics 13, 475 (2012).
58. Katoh, K. & Standley, D.M. MAFFT multiple-sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772-780 (2013).
59. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post analysis of large phylogenies. Bioinformatics 30, 1312-1313 (2014).
60. Price, A.L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904-909 (2006).
61. Bhattacharya, T. et al. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315, 1583-1586 (2007).
62. R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2016).
63. Magri, A. et al. Rethinking the old antiviral drug moroxydine: discovery of novel analogues as anti-hepatitis C virus (HCV) agents. Bioorg. Med. Chem. Lett. 25, 5372-5376 (2015).
64. Rojas, Á. et al. Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype, and modulates gene expression in vivo and in vitro. J. Viral Hepat. 21, 19-24 (2014).